Hypertension Therapeutics
1. Adempas patent expiration
Treatment: Treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinic...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6743798 | BAYER HLTHCARE | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
Jul, 2019
(6 years ago) | |
| US10662188 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate |
Feb, 2034
(8 years from now) | |
| US11203593 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
Feb, 2034
(8 years from now) | |
| US7173037 | BAYER HLTHCARE | Carbamate-substituted pyrazolopyridines |
Dec, 2026
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 08, 2020 |
| Orphan Drug Exclusivity(ODE-53) | Oct 08, 2020 |
Drugs and Companies using RIOCIGUAT ingredient
NCE-1 date: 08 October, 2017
Market Authorisation Date: 08 October, 2013
Dosage: TABLET
How can I launch a generic of ADEMPAS before it's drug patent expiration?
More Information on Dosage
ADEMPAS family patents
2. Benicar patent expiration
Treatment: Use as an antihypertensive agent; Treatment of hypertension
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5616599 | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Apr, 2016
(9 years ago) | |
| US6878703 | COSETTE | Pharmaceutical composition |
Nov, 2021
(4 years ago) | |
|
US6878703 (Pediatric) | COSETTE | Pharmaceutical composition |
May, 2022
(3 years ago) | |
|
US5616599 (Pediatric) | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Oct, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 04, 2013 |
| Pediatric Exclusivity(PED) | Aug 04, 2013 |
Drugs and Companies using OLMESARTAN MEDOXOMIL ingredient
Market Authorisation Date: 25 April, 2002
Dosage: TABLET
How can I launch a generic of BENICAR before it's drug patent expiration?
More Information on Dosage
BENICAR family patents
3. Bystolic patent
expiration
Treatment: Treatment of hypertension
BYSTOLIC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6545040 | ALLERGAN | Method of lowering the blood pressure |
Dec, 2021
(4 years ago) | |
| US5759580 | ALLERGAN | Compositions containing micronized nebivolol |
Jun, 2015
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 17, 2012 |
Drugs and Companies using NEBIVOLOL HYDROCHLORIDE ingredient
NCE-1 date: 18 December, 2011
Market Authorisation Date: 17 December, 2007
Dosage: TABLET
How can I launch a generic of BYSTOLIC before it's drug patent expiration?
More Information on Dosage
BYSTOLIC family patents
4. Cialis patent expiration
Treatment: Erectile dysfunction; Treatment of erectile dysfunction; Treatment of sexual dysfunction
CIALIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6943166 (Pediatric) | LILLY | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Oct, 2020
(5 years ago) | |
| US6821975 | LILLY | Beta-carboline drug products |
Nov, 2020
(5 years ago) | |
| US6140329 | LILLY | Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence |
Jul, 2016
(9 years ago) | |
| US7182958 | LILLY | β-carboline pharmaceutical compositions |
Apr, 2020
(5 years ago) | |
|
US5859006 (Pediatric) | LILLY | Tetracyclic derivatives; process of preparation and use |
May, 2018
(7 years ago) | |
|
US6821975 (Pediatric) | LILLY | Beta-carboline drug products |
May, 2021
(4 years ago) | |
| US5859006 | LILLY | Tetracyclic derivatives; process of preparation and use |
Nov, 2017
(8 years ago) | |
|
US7182958 (Pediatric) | LILLY | β-carboline pharmaceutical compositions |
Oct, 2020
(5 years ago) | |
| US6943166 | LILLY | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Apr, 2020
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-641) | Oct 06, 2014 |
| New Indication(I-642) | Oct 06, 2014 |
| M(M-219) | Feb 15, 2021 |
| Pediatric Exclusivity(PED) | Aug 15, 2021 |
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 07 January, 2008
Dosage: TABLET
How can I launch a generic of CIALIS before it's drug patent expiration?
More Information on Dosage
CIALIS family patents
5. Cleviprex patent expiration
Treatment: Cleviprex is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable
CLEVIPREX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5856346 | CHIESI | Short-acting dihydropyridines |
Jan, 2021
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5856346 | CHIESI | Short-acting dihydropyridines |
Jan, 2021
(5 years ago) | |
| US5739152 | CHIESI | Pharmaceutical emulsion |
Apr, 2015
(10 years ago) | |
| US8658676 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(5 years from now) | |
| US11103490 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(5 years from now) | |
| US10010537 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2013 |
Drugs and Companies using CLEVIDIPINE ingredient
NCE-1 date: 01 August, 2012
Market Authorisation Date: 01 August, 2008
Dosage: EMULSION
How can I launch a generic of CLEVIPREX before it's drug patent expiration?
More Information on Dosage
CLEVIPREX family patents
6. Edarbi patent expiration
Treatment: Treatment of hypertension
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7157584 | AZURITY | Benzimidazole derivative and use thereof |
May, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5583141 | AZURITY | Heterocyclic compounds and their use as angiotensin antagonists |
Dec, 2013
(12 years ago) | |
| US5958961 | AZURITY | Pharmaceutical composition for angiotensin II-mediated diseases |
Jun, 2014
(11 years ago) | |
| US7572920 | AZURITY | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(1 year, 2 days ago) | |
| US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2016 |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient
NCE-1 date: 25 February, 2015
Market Authorisation Date: 25 February, 2011
Dosage: TABLET
How can I launch a generic of EDARBI before it's drug patent expiration?
More Information on Dosage
EDARBI family patents
7. Inomax patent expiration
Treatment: A method of providing nitric oxide therapy to a patient; A method of purging a nitric oxide delivery system; Prevention or treatment of reversible vasoconstriction by the inhalation of nitric oxide wi...
INOMAX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11931377 | MALLINCKRODT IRELAND | Methods of administering inhaled nitric oxide gas |
Jun, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6125846 (Pediatric) | MALLINCKRODT IRELAND | Purge system for nitric oxide administration apparatus |
Nov, 2017
(8 years ago) | |
| US5732693 | MALLINCKRODT IRELAND | Pause control of nitric oxide therapy |
Dec, 2016
(9 years ago) | |
| US5752504 | MALLINCKRODT IRELAND | System for monitoring therapy during calibration |
Dec, 2016
(9 years ago) | |
| US6125846 | MALLINCKRODT IRELAND | Purge system for nitric oxide administration apparatus |
May, 2017
(8 years ago) | |
|
US5485827 (Pediatric) | MALLINCKRODT IRELAND | Methods and devices for treating plumonary vasoconstriction and asthma |
Jul, 2013
(12 years ago) | |
|
US5558083 (Pediatric) | MALLINCKRODT IRELAND | Nitric oxide delivery system |
May, 2014
(11 years ago) | |
|
US5873359 (Pediatric) | MALLINCKRODT IRELAND | Methods and devices for treating pulmonary vasoconstriction and asthma |
Jul, 2013
(12 years ago) | |
| US5873359 | MALLINCKRODT IRELAND | Methods and devices for treating pulmonary vasoconstriction and asthma |
Jan, 2013
(12 years ago) | |
|
US5752504 (Pediatric) | MALLINCKRODT IRELAND | System for monitoring therapy during calibration |
Jun, 2017
(8 years ago) | |
|
US5732693 (Pediatric) | MALLINCKRODT IRELAND | Pause control of nitric oxide therapy |
Jun, 2017
(8 years ago) | |
| US8776795 | MALLINCKRODT IRELAND | Gas delivery device and system |
Jan, 2031
(4 years from now) | |
| US8573210 | MALLINCKRODT IRELAND | Nitric oxide delivery device |
Jan, 2031
(4 years from now) | |
| US5558083 | MALLINCKRODT IRELAND | Nitric oxide delivery system |
Nov, 2013
(12 years ago) | |
| US5485827 | MALLINCKRODT IRELAND | Methods and devices for treating plumonary vasoconstriction and asthma |
Jan, 2013
(12 years ago) | |
| US9265911 | MALLINCKRODT IRELAND | Gas delivery device and system |
Jan, 2031
(4 years from now) | |
| US9295802 | MALLINCKRODT IRELAND | Gas delivery device and system |
Jan, 2031
(4 years from now) | |
| US8282966 | MALLINCKRODT IRELAND | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Jun, 2029
(3 years from now) | |
| US8293284 | MALLINCKRODT IRELAND | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Jun, 2029
(3 years from now) | |
| US8291904 | MALLINCKRODT IRELAND | Gas delivery device and system |
Jan, 2031
(4 years from now) | |
| US8846112 | MALLINCKRODT IRELAND | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Jun, 2029
(3 years from now) | |
| US8776794 | MALLINCKRODT IRELAND | Nitric oxide delivery device |
Jan, 2031
(4 years from now) | |
| US8795741 | MALLINCKRODT IRELAND | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Jun, 2029
(3 years from now) | |
| US9279794 | MALLINCKRODT IRELAND | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Feb, 2035
(9 years from now) | |
| US8431163 | MALLINCKRODT IRELAND | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Jun, 2029
(3 years from now) | |
| US9408993 | MALLINCKRODT IRELAND | Nitric oxide delivery device |
Jan, 2031
(4 years from now) | |
| US9770570 | MALLINCKRODT IRELAND | Apparatus and method for monitoring nitric oxide delivery |
May, 2036
(10 years from now) | |
| US8573209 | MALLINCKRODT IRELAND | Gas delivery device and system |
Jan, 2031
(4 years from now) | |
|
US8282966 (Pediatric) | MALLINCKRODT IRELAND | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Dec, 2029
(3 years from now) | |
|
US8291904 (Pediatric) | MALLINCKRODT IRELAND | Gas delivery device and system |
Jul, 2031
(5 years from now) | |
|
US8293284 (Pediatric) | MALLINCKRODT IRELAND | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Dec, 2029
(3 years from now) | |
|
US8431163 (Pediatric) | MALLINCKRODT IRELAND | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Dec, 2029
(3 years from now) | |
|
US8776795 (Pediatric) | MALLINCKRODT IRELAND | Gas delivery device and system |
Jul, 2031
(5 years from now) | |
|
US8776794 (Pediatric) | MALLINCKRODT IRELAND | Nitric oxide delivery device |
Jul, 2031
(5 years from now) | |
|
US8795741 (Pediatric) | MALLINCKRODT IRELAND | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Dec, 2029
(3 years from now) | |
|
US8573209 (Pediatric) | MALLINCKRODT IRELAND | Gas delivery device and system |
Jul, 2031
(5 years from now) | |
|
US8846112 (Pediatric) | MALLINCKRODT IRELAND | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Dec, 2029
(3 years from now) | |
|
US8573210 (Pediatric) | MALLINCKRODT IRELAND | Nitric oxide delivery device |
Jul, 2031
(5 years from now) | |
|
US9295802 (Pediatric) | MALLINCKRODT IRELAND | Gas delivery device and system |
Jul, 2031
(5 years from now) | |
|
US9408993 (Pediatric) | MALLINCKRODT IRELAND | Nitric oxide delivery device |
Jul, 2031
(5 years from now) | |
|
US9265911 (Pediatric) | MALLINCKRODT IRELAND | Gas delivery device and system |
Jul, 2031
(5 years from now) | |
|
US9279794 (Pediatric) | MALLINCKRODT IRELAND | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Aug, 2035
(9 years from now) | |
|
US11931377 (Pediatric) | MALLINCKRODT IRELAND | Methods of administering inhaled nitric oxide gas |
Dec, 2029
(3 years from now) | |
|
US9770570 (Pediatric) | MALLINCKRODT IRELAND | Apparatus and method for monitoring nitric oxide delivery |
Nov, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-132) | Dec 21, 2013 |
| Pediatric Exclusivity(PED) | Jun 21, 2014 |
| M(M-167) | Oct 09, 2018 |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 23 December, 1999
Dosage: GAS
How can I launch a generic of INOMAX before it's drug patent expiration?
More Information on Dosage
INOMAX family patents
8. Inspra patent expiration
Treatment: Treatment of conditions for which an aldosterone receptor blocker is indicated, such as hypertension, heart failure, and post-myocardial inf...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6863902 | UPJOHN | Immediate release eplerenone compositions |
Apr, 2020
(5 years ago) | |
|
US6558707 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(5 years ago) | |
|
US6747020 (Pediatric) | UPJOHN | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
May, 2020
(5 years ago) | |
|
US7157101 (Pediatric) | UPJOHN | Micronized eplerenone compositions |
Jun, 2020
(5 years ago) | |
|
US6495165 (Pediatric) | UPJOHN | Eplerenone compositions having improved bioavailability |
Jun, 2020
(5 years ago) | |
|
US6410524 (Pediatric) | UPJOHN | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
May, 2020
(5 years ago) | |
|
US6410054 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(5 years ago) | |
|
US6534093 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(5 years ago) | |
|
US6863902 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Oct, 2020
(5 years ago) | |
| US6410524 | UPJOHN | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
Nov, 2019
(6 years ago) | |
| US6410054 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(6 years ago) | |
| US6747020 | UPJOHN | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
Nov, 2019
(6 years ago) | |
| US6534093 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(6 years ago) | |
| US7157101 | UPJOHN | Micronized eplerenone compositions |
Dec, 2019
(6 years ago) | |
| US6495165 | UPJOHN | Eplerenone compositions having improved bioavailability |
Dec, 2019
(6 years ago) | |
| US6558707 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jul 31, 2011 |
Drugs and Companies using EPLERENONE ingredient
Market Authorisation Date: 27 September, 2002
Dosage: TABLET
How can I launch a generic of INSPRA before it's drug patent expiration?
More Information on Dosage
INSPRA family patents
9. Letairis patent expiration
Treatment: Method to treat pulmonary hypertension by administering ambrisentan to a patient; Treatment of pulmonary arterial
LETAIRIS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5703017 | GILEAD | 3-(Het) arylcarboxylic acid derivatives, their preparation and intermediates for their preparation |
Dec, 2014
(11 years ago) | |
| US7601730 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(10 years ago) | |
| USRE42462 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Jul, 2018
(7 years ago) | |
| US7109205 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(10 years ago) | |
| US5840722 | GILEAD | Use of carboxylic acid derivatives as drugs |
Nov, 2015
(10 years ago) | |
| US8349843 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(10 years ago) | |
| US9474752 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(1 year, 10 months from now) | |
| US9549926 | GILEAD | Compositions and methods of treating pulmonary hypertension |
Oct, 2031
(5 years from now) | |
| US8377933 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 15, 2012 |
| Orphan Drug Exclusivity(ODE) | Jun 15, 2014 |
| New Indication(I-716) | Oct 02, 2018 |
Drugs and Companies using AMBRISENTAN ingredient
NCE-1 date: 16 June, 2011
Market Authorisation Date: 15 June, 2007
Dosage: TABLET
How can I launch a generic of LETAIRIS before it's drug patent expiration?
More Information on Dosage
LETAIRIS family patents
10. Omlonti patent expiration
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10774072 | OCUVEX THERAP | Crystal of N-substituted sulfonamide compound |
Jun, 2035
(9 years from now) | |
| US8648097 | OCUVEX THERAP | Pyridylaminoacetic acid compound |
Oct, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12295946 | OCUVEX THERAP | NA |
Jan, 2035
(9 years from now) | |
| US12290511 | OCUVEX THERAP | NA |
Dec, 2038
(12 years from now) | |
| US11666563 | OCUVEX THERAP | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
Jul, 2039
(13 years from now) | |
| US11197849 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US10702511 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US10179127 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US9415038 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| USRE48183 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US11793798 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US10765750 | OCUVEX THERAP | Pharmaceutical composition containing pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US8685986 | OCUVEX THERAP | Medical composition for treatment or prophylaxis of glaucoma |
Oct, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: 22 September, 2026
Market Authorisation Date: 22 September, 2022
Dosage: SOLUTION
More Information on Dosage
OMLONTI family patents
11. Opsumit patent expiration
Treatment: Method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhi...
OPSUMIT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7094781 | ACTELION | Sulfamides and their use as endothelin receptor antagonists |
Dec, 2025
(a month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268847 | ACTELION | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor |
Apr, 2029
(3 years from now) | |
| US9265762 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
May, 2027
(1 year, 4 months from now) | |
| US10946015 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Sep, 2026
(8 months from now) | |
| US8367685 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Oct, 2028
(2 years from now) | |
|
US8268847 (Pediatric) | ACTELION | NA |
Oct, 2029
(3 years from now) | |
|
US7094781 (Pediatric) | ACTELION | NA |
Jun, 2026
(4 months from now) | |
|
US8367685 (Pediatric) | ACTELION | NA |
Apr, 2029
(3 years from now) | |
|
US9265762 (Pediatric) | ACTELION | NA |
Nov, 2027
(1 year, 10 months from now) | |
|
US10946015 (Pediatric) | ACTELION | NA |
Mar, 2027
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 18, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 18, 2020 |
| Orphan Drug Exclusivity(ODE-54) | Oct 18, 2020 |
| M(M-187) | Feb 28, 2028 |
| Pediatric Exclusivity(PED) | Aug 28, 2028 |
Drugs and Companies using MACITENTAN ingredient
NCE-1 date: 29 August, 2027
Market Authorisation Date: 18 October, 2013
Dosage: TABLET
How can I launch a generic of OPSUMIT before it's drug patent expiration?
More Information on Dosage
OPSUMIT family patents
12. Remodulin patent expiration
Treatment: Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration; Treatment of pulmonary
REMODULIN's oppositions filed in EPO
REMODULIN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(2 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(2 years from now) | |
| US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(2 years from now) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8658694 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(2 years from now) | |
| US5153222 | UNITED THERAP | Method of treating pulmonary hypertension with benzidine prostaglandins |
Oct, 2014
(11 years ago) | |
| US6765117 | UNITED THERAP | Process for stereoselective synthesis of prostacyclin derivatives |
Oct, 2017
(8 years ago) | |
| US8653137 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(2 years from now) | |
| US7999007 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Mar, 2029
(3 years from now) | |
| US9199908 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 7 months ago) | |
| US9713599 | UNITED THERAP | Parenteral formulations of treprostinil |
Dec, 2024
(1 year, 24 days ago) | |
| US10695308 | UNITED THERAP | Inhalation formulations of treprostinil |
Dec, 2024
(1 year, 24 days ago) | |
| US10076505 | UNITED THERAP | Inhalation formulations of Treprostinil |
Dec, 2024
(1 year, 24 days ago) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 28 September, 2023
Dosage: INJECTABLE; SOLUTION
How can I launch a generic of REMODULIN before it's drug patent expiration?
More Information on Dosage
REMODULIN family patents
13. Tracleer patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5292740 | ACTELION | Sulfonamides |
Nov, 2015
(10 years ago) | |
| US8309126 | ACTELION | Dispersible bosentan tablet |
May, 2026
(4 months from now) | |
| US7959945 | ACTELION | Dispersible bosentan tablet |
Dec, 2027
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-607) | Aug 07, 2012 |
| New Product(NP) | Sep 05, 2020 |
| New Patient Population(NPP) | Sep 05, 2020 |
| Orphan Drug Exclusivity(ODE) | Sep 05, 2024 |
| ODE*(ODE*) | Sep 05, 2024 |
| Orphan Drug Exclusivity(ODE-161) | Sep 05, 2024 |
Drugs and Companies using BOSENTAN ingredient
Market Authorisation Date: 20 November, 2001
Dosage: TABLET; TABLET, FOR SUSPENSION
How can I launch a generic of TRACLEER before it's drug patent expiration?
More Information on Dosage
TRACLEER family patents
14. Tryvio patent expiration
Treatment: Treatment of hypertension in combination with other antihypertensive drugs, including an angiotensin converting enzyme inhibitor, to lower b...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8324232 | IDORSIA | 4-pyrimidinesulfamide derivative |
Sep, 2029
(3 years from now) | |
| US10919881 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Feb, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11787782 | IDORSIA | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Mar, 2038
(12 years from now) | |
| US11680058 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Jul, 2038
(12 years from now) | |
| US11174247 | IDORSIA | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Nov, 2037
(11 years from now) | |
| US12297189 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Feb, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2029 |
Drugs and Companies using APROCITENTAN ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 19 March, 2024
Dosage: TABLET
More Information on Dosage
TRYVIO family patents
15. Uptravi patent expiration
Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist...
UPTRAVI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7205302 | ACTELION | Heterocyclic compound derivatives and medicines |
Oct, 2026
(9 months from now) | |
| US8791122 | ACTELION | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same |
Aug, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173881 | ACTELION | Therapeutic compositions containing macitentan |
Aug, 2029
(3 years from now) | |
| US9284280 | ACTELION | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Jun, 2030
(4 years from now) | |
| US10828298 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide |
Dec, 2036
(10 years from now) | |
| US10821108 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Dec, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2020 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2022 |
| Orphan Drug Exclusivity(ODE-106) | Dec 21, 2022 |
Drugs and Companies using SELEXIPAG ingredient
NCE-1 date: 22 December, 2019
Market Authorisation Date: 21 December, 2015
Dosage: TABLET; POWDER
How can I launch a generic of UPTRAVI before it's drug patent expiration?
More Information on Dosage
UPTRAVI family patents
16. Vyzulta patent expiration
Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension
VYZULTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6211233 | BAUSCH AND LOMB | Prostaglandin pharmaceutical compositions |
Jun, 2018
(7 years ago) | |
| US8058467 | BAUSCH AND LOMB | Prostaglandin derivatives |
Feb, 2029
(3 years from now) | |
| US7910767 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(1 year, 4 days ago) | |
| US7273946 | BAUSCH AND LOMB | Prostaglandin derivatives |
Oct, 2025
(3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7629345 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(1 year, 4 days ago) | |
Drugs and Companies using LATANOPROSTENE BUNOD ingredient
Market Authorisation Date: 02 November, 2017
Dosage: SOLUTION/DROPS
How can I launch a generic of VYZULTA before it's drug patent expiration?
More Information on Dosage
VYZULTA family patents